141 results on '"Lichtenstein, Gary R"'
Search Results
2. S844 Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
3. S903 Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
4. S1060 Guselkumab Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the QUASAR Phase 3 Induction Study
5. S907 Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
6. Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn’s Disease
7. Biosimilars in Inflammatory Bowel Disease
8. S0744 Supratherapeutic Infliximab Levels Do Not Predict a Higher Risk of Infectious and Non-Infectious Complications in Adult Patients With Crohn’s Disease; Whereas Shorter Duration of Exposure Predicts These Outcomes
9. S0901 Tofacitinib for the Treatment of Ulcerative Colitis: An Update on the Analysis of Malignancy Rates From the Ulcerative Colitis Clinical Program as of May 2019
10. S0750 A Decade Long Trend of Therapeutic Drug Monitoring at a Tertiary Referral Center: Shifting Focus From Reactive to Proactive - Is This Useful?
11. S0751 Development of a Composite Weighted Model to Predict Infliximab Persistence in Patients With Crohn’s Disease
12. S0752 Infliximab Level <3 µg/ml Predicts Immune-Mediated Loss of Response in Patients With Crohn’s Disease
13. S0740 Economic Impact and Health-Care Utilization Trends Related to Hospitalization and Hospital Readmissions in Patients With Inflammatory Bowel Disease (IBD): A U.S. Population Cohort Study
14. Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician
15. A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases
16. Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy
17. 712 Predictors of Ectopic Pregnancy Among Women With Inflammatory Bowel Disease: A Population-Based Cohort Analysis
18. 840 Patient Characteristics and Outcomes Associated With Cannabis Abuse or Dependence Among Hospitalized Patients With IBD: A U.S. Time-Trend Analysis and Population-Based Cohort Study
19. 705 Tofacitinib for the Treatment of Ulcerative Colitis: An Update on the Analysis of Malignancy Rates From the UC Clinical Program
20. 673 The Peripartum Risk of Deep Vein Thrombosis and Pulmonary Embolism in Women With Inflammatory Bowel Disease: A Population-Based Cohort Analysis
21. 706 Impact of Baseline Corticosteroid Therapy on Tofacitinib Induction Efficacy and Infection Risk in Patients With Ulcerative Colitis: Data From Global Clinical Trials
22. 639 A Multimodal Intervention Reduces Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Disease
23. 704 Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 5.5 Years of Treatment
24. 151 Teaching Hospitals Have Lower Adjusted Rates of Hospital-Onset C. difficile Infection Compared to Non-Teaching Hospitals
25. 841 The Impact of Inpatient Intravenous Opioids on Future Outpatient Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Disease
26. Response to Chapman and Jones
27. Response to Ribaldone
28. Response to Chamberlin and Borody
29. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report
30. Weekend Discharges Are Not Associated with Increased Readmission Rates for Ulcerative Colitis Hospitalizations
31. Baseline Albumin Level Is Not a Significant Predictor of Tofacitinib Efficacy in Patients with Ulcerative Colitis: Results of Multivariate Exposure-Response Analysis
32. A Validated User-Friendly Predictive Tool to Identify Colectomy Risk in Patients with Mild, Moderate, and Severe Ulcerative Colitis
33. Lack of Discrepancy in Inflammatory Bowel Disease Hospitalization Outcomes Among Patients of Different Race or Ethnicity
34. Emergency Department Visits for Inflammatory Bowel Disease Patients Are Increasing at a Steady Rate
35. The Influence of Inflammatory Bowel Disease on the Outcome of Patients With Acute Stroke
36. Infliximab Drug Trough Levels Do Not Correlate With Infectious Complication Risk in Patients With Crohnʼs Disease
37. A Comparison of Hospitalization Outcomes for Inflammatory Bowel Disease in Academic vs. Nonacademic Medical Centers
38. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment
39. Correction: ACG Clinical Guideline: Management of Crohn's Disease in Adults
40. ACG Clinical Guideline: Management of Crohn's Disease in Adults
41. Safety and Efficacy of Vedolizumab Use in Older Patients With Inflammatory Bowel Disease
42. Complications of Crohnʼs Disease and Ulcerative Colitis: Understanding the Lifetime Risks
43. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study
44. Risk and Factors Impacting Incidence of Herpes Zoster (HZ) in Nationwide Cohort of IBD and Non-IBD Patients: 2017 Presidential Poster Award
45. The Economic Burden of Crohnʼs Disease and Ulcerative Colitis in the United States: A Lifetime Healthcare Cost Analysis: 2017 Presidential Poster Award
46. A Statistical Model to Predict Future Colectomy in Patients With Ulcerative Colitis
47. Elevated C-reactive Protein Predicts Future Corticosteroid Use in Patients With Ulcerative Colitis
48. Statistical Models to Predict Early and Late Hospitalization in Patients With Ulcerative Colitis
49. Editorial: Endoscopic Scoring Systems in Crohn’s Disease for Evaluation of Responsiveness to Treatment: Are we Ready for the Prime Time of Endoscopic Assessment?
50. Corrigendum: ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.